Ibandronate (Boniva) for Treatment and Prevention of Osteoporosis in Postmenopausal Women
Am Fam Physician. 2006 Jan 15;73(2):305-306.
Ibandronate (Boniva) is the newest oral bisphosphonate approved for the treatment and prevention of osteoporosis in women who are postmenopausal. It is the first drug in its class that can be taken daily or monthly.
|Name||Starting dosage||Dose form||Approximate monthly cost*|
2.5 mg daily
2.5− or 150-mg tablets
$78 (either dosage)
150 mg monthly
*—Average wholesale cost, based on Red Book, Montvale, N.J.: Medical Economics Data, 2005.
Ibandronate, like other bisphosphonates administered orally, may cause esophagitis, esophageal ulcer, or gastric ulcer. These risks may be increased in patients taking concurrent nonsteroidal anti-inflammatory drugs. Ibandronate is not recommended for use in patients with severe renal impairment and has not been studied in patients with hepatic impairment.1 The U.S. Food and Drug Administration has classified ibandronate category C for use during pregnancy.
Adverse effects with ibandronate most commonly are gastrointestinal and include dyspepsia, gastroenteritis, and nausea. They are comparable to the adverse effects of other drugs in the same class.2,3 In two clinical trials, 7 percent and 7.5 percent of participants in the ibandronate 2.5 mg daily groups dropped out because of medication-related adverse effects.2,3 Adverse effects that were reported in greater than 5 percent of patients taking ibandronate included back pain, headache, bronchitis, and myalgias. The overall adverse-effect profiles of the daily and monthly preparations were similar.4
There are many questions regarding the effectiveness of ibandronate in preventing outcomes of importance to patients. Daily ibandronate was compared with placebo in 2,929 postmenopausal women with a prior vertebral fracture.3 Treatment decreased the absolute risk of new, symptomatic, radiographically confirmed vertebral fracture from 5.3 to 2.8 percent over three years (absolute risk reduction 2.3 percent; number needed to treat = 43 for three years).3 There was no difference in the likelihood of clinical nonvertebral fracture between placebo and ibandronate. The 2.5-mg daily and 150-mg monthly dosages of ibandronate were equivalent in terms of percent change in lumbar spine bone mineral density from baseline to one year. The effects of ibandronate on rates of hip fracture, death, and symptomatic vertebral fracture have not been assessed.4 Data on the fracture prevention of ibandronate in patients with osteoporosis but without previous fracture are lacking.5 No bisphosphonate has been compared with adequate doses of calcium and vitamin D.5
The cost of ibandronate is approximately $78 per month for either dosage. Weekly alendronate (Fosamax) costs $77 per month and weekly risedronate (Actonel) costs $74 per month.
Ibandronate can be taken once daily or once monthly, similar to the daily or intermittent formulations of alendronate and risedronate. It should be taken only with water, at a time when the patient will be able to remain upright for one hour following the dose, and should not be taken within one hour of eating or of ingesting any other medication. Products containing calcium, aluminum, magnesium, or iron (e.g., milk, many foods, antacids) interfere with absorption of ibandronate. Thus, monthly dosing may be more convenient for some patients.
Ibandronate is a bisphosphonate that can be taken daily or monthly. The daily dosage has been shown to decrease vertebral fractures in women with osteoporosis and a history of previous vertebral fractures. Neither formulation has been shown to reduce the risk of hip fracture or other nonvertebral fracture, nor to reduce fractures in women without prior fracture. Ibandronate has not been compared directly with other bisphosphonates or with adequate daily doses of calcium and vitamin D. The convenience of monthly dosing needs to be balanced against the lack of data on fracture prevention.
1. Ibandronate. In: DRUGDEX System. Greenwood Village, Colo.: Thompson Micromedex, 2004.
2. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH III, Ensrud KE, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004;19:11–8.
3. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.
4. Palacioz K. Boniva (ibandronate) monthly or daily now available. Pharmacist’s Letter. 2005;21:210420.
5. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005:293;2257–64.
STEPS drug updates cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each update provides an independent review of a new medication by authors who have no financial association with the drug manufacturer.
The series coordinator is Allen F. Shaughnessy, Pharm.D., Tufts University Family Medicine Residency Program, Boston, Mass.
Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions